GlaxoSmithKline, Regeneron partner to generate genetic sequence data

Thursday, March 23, 2017

Regeneron Pharmaceuticals has announced a major research initiative among the Regeneron Genetics Center (RGC), U.K. Biobank and GSK to generate genetic sequence data from the 500,000 volunteer participants in the U.K. Biobank resource. The initiative will enable researchers to gain valuable insights to support advances in the development of new medicines for a wide range of serious and life threatening diseases.

[Read More]

FDA, EU drug inspectors ink Mutual Recognition Agreement

Monday, March 6, 2017

The U.S. and the European Union (EU) completed an exchange of letters to amend the Pharmaceutical Annex to the 1998 U.S.-EU Mutual Recognition Agreement. Under this agreement, U.S. and EU regulators will be able to utilize each other’s good manufacturing practice inspections of pharmaceutical manufacturing facilities.

[Read More]

Merz Pharmaceuticals, SAFE to launch patient-centric spasticity initiative

Tuesday, February 28, 2017

Merz Pharmaceuticals has announced the launch of Life With Spasticity, an educational online platform intended to provide comprehensive information and motivational support for stroke survivors who experience post-stroke spasticity. Designed by and for individuals living with spasticity, the project is funded by Merz and has been developed in partnership with Stroke Alliance For Europe (SAFE).

[Read More]

Genedata expands in the U.K.

Wednesday, February 22, 2017

Genedata, a provider of advanced software solutions for biopharmaceutical and biotech research and development (R&D), announced the establishment of Genedata Limited as a new subsidiary in the U.K. The company is headed by Managing Director Kevin Teburi, a recognized expert in life science informatics. Creating the U.K. subsidiary reinforces Genedata’s commitment to collaborate closely with its rapidly growing client base in the U.K., one of the most exciting biotech hubs in the world, in particular in the high-potential field of precision medicine. 

[Read More]

Luxcel Biosciences, Axiogenesis, BMG LABTECH to develop cell metabolism analysis platform

Thursday, February 16, 2017

Three European technology SMEs, together with two research institutions, Oxford University and Imperial College London, have been awarded €2.5 million funding from the European commission under the H2020 Fast Track to Innovation (FTI) pilot, to develop and launch a cell metabolism analysis platform that is predicted to be part of routine in vitro cell biology and drug development. 

[Read More]